| MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road CJ Caunt, MJ Sale, PD Smith, SJ Cook Nature Reviews Cancer 15 (10), 577-592, 2015 | 648 | 2015 |
| Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells AS Little, K Balmanno, MJ Sale, S Newman, JR Dry, M Hampson, ... Science signaling 4 (166), ra17-ra17, 2011 | 250 | 2011 |
| Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling SJ Cook, K Stuart, R Gilley, MJ Sale The FEBS journal 284 (24), 4177-4195, 2017 | 184 | 2017 |
| Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation CL Cope, R Gilley, K Balmanno, MJ Sale, KD Howarth, M Hampson, ... Journal of cell science 127 (4), 788-800, 2014 | 96 | 2014 |
| Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors MJ Sale, E Minihane, NR Monks, R Gilley, FM Richards, KP Schifferli, ... Nature communications 10 (1), 5167, 2019 | 70 | 2019 |
| The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance MJ Sale, SJ Cook Biochemical Journal 450 (2), 285-294, 2013 | 67 | 2013 |
| MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance MJ Sale, K Balmanno, J Saxena, E Ozono, K Wojdyla, RE McIntyre, ... Nature Communications 10 (1), 2030, 2019 | 60 | 2019 |
| SLFN11 informs on standard of care and novel treatments in a wide range of cancer models C Winkler, J Armenia, GN Jones, L Tobalina, MJ Sale, T Petreus, T Baird, ... British Journal of Cancer 124 (5), 951-962, 2021 | 59 | 2021 |
| Lysine acetylation controls local protein conformation by influencing proline isomerization FS Howe, I Boubriak, MJ Sale, A Nair, D Clynes, A Grijzenhout, ... Molecular cell 55 (5), 733-744, 2014 | 46 | 2014 |
| RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity P Castel, S Dharmaiah, MJ Sale, S Messing, G Rizzuto, ... Proceedings of the National Academy of Sciences 118 (33), e2103261118, 2021 | 37 | 2021 |
| That which does not kill me makes me stronger; combining ERK 1/2 pathway inhibitors and BH 3 mimetics to kill tumour cells and prevent acquired resistance MJ Sale, SJ Cook British journal of pharmacology 169 (8), 1708-1722, 2013 | 31 | 2013 |
| Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer MJ Sale, SJ Cook Biochemical Society Transactions 42 (4), 776-783, 2014 | 30 | 2014 |
| Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling AS Little, K Balmanno, MJ Sale, PD Smith, SJ Cook Biochemical Society Transactions 40 (1), 73-78, 2012 | 25 | 2012 |
| Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization LC Young, R Goldstein de Salazar, SW Han, ZYS Huang, A Merk, M Drew, ... Proceedings of the National Academy of Sciences 120 (5), e2208960120, 2023 | 17 | 2023 |
| RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy A Cuevas-Navarro, M Wagner, R Van, M Swain, S Mo, J Columbus, ... Science Advances 9 (28), eadf4766, 2023 | 16 | 2023 |
| A correction to the research article titled:" Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells … AS Little, K Balmanno, MJ Sale, S Newman, JR Dry, M Hampson, ... Science signaling 4 (170), er2-er2, 2011 | 9 | 2011 |
| ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1 K Balmanno, AM Kidger, DP Byrne, MJ Sale, N Nassman, PA Eyers, ... Biochemical Journal 480 (9), 587-605, 2023 | 7 | 2023 |
| Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction MJ Sale, K Balmanno, SJ Cook Cancer Drug Resistance 2 (2), 365, 2019 | 7 | 2019 |
| The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G1 cell-cycle arrest and not a direct effect on BIK protein stability MJ Sale, SJ Cook Biochemical Journal 459 (3), 513-524, 2014 | 7 | 2014 |
| Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance HN Vasudevan, E Payne, CL Delley, S John Liu, K Mirchia, MJ Sale, ... Nature communications 15 (1), 477, 2024 | 6 | 2024 |
Simon CookSignalling Programme, The Babraham InstituteVerified email at babraham.ac.uk
